The U.S. Supreme Court on June 21 declined to hear AbbVie Inc.’s challenge to a lower court’s decision that the company violated federal antitrust law by pursuing a “sham” patent complaint against rival Perrigo Co. over AbbVie’s blockbuster testosterone replacement drug AndroGel.
Allele Biotechnology and Pharmaceuticals filed lawsuits against Regeneron Pharmaceuticals, as well as Pfizer and Germany’s BioNTech, claiming the companies infringed on Allele’s patented mNeonGreen technology in the development of their Covid-19 treatments.
The U.S. FDA approved Amneal Pharmaceuticals’ generic version of Novartis’ Exelon Patch (Rivastigmine Transdermal System) for dementia related to Alzheimer’s and Parkinson’s diseases.
Ironwood Pharmaceuticals Inc. and Allergan plc announced that the companies reached an agreement with Mylan Pharmaceuticals Inc. resolving patent litigations brought in response to Mylan’s abbreviated new drug applications seeking approval to market generic versions of Linzess (linaclotide) before the expiration of the companies’ applicable patents.
Indivior said a U.S. court expedited a generic rival’s appeal against a preliminary injunction that blocked the sale of a copycat version of the British drugmaker’s blockbuster opioid addiction treatment.
Indivior Plc’s shares jumped more than 33 percent after a U.S. court blocked a rival from selling a cheaper copycat of the British drugmaker’s bestselling opioid addiction treatment.
South Korea’s Samsung Bioepis started U.S sales of its copy of Johnson & Johnson’s blockbuster rheumatoid arthritis drug Remicade.
Eli Lilly entered into a settlement agreement with generic companies to resolve pending patent litigation regarding the Cialis (tadalafil) unit dose patent.
Bristol-Myers Squibb and Ono Pharmaceutical announced a global patent license agreement with Merck & Co. to settle all patent-infringement litigation related to Merck’s PD-1 antibody Keytruda.
AstraZeneca has entered into an agreement with Sandoz, the generic pharmaceuticals division of Novartis, to resolve Faslodex patent litigation in the U.S.